Month: March 2019

March 14, 2019
European Commission approves Roche’s Hemlibra for people with severe haemophilia A

The European Commission has approved emicizumab (Hemlibra) as prophylaxis in people with severe haemophilia A without factor VIII inhibitors. The decision endorses a positive opinion from the Agency’s Committee for Medicinal Products for Human Use on January 31st. Emicizumab was approved for prophylaxis in people with inhibitors in February 2018 and was approved for NHS …

Read article
March 5, 2019
European Principles of Inhibitor Management now on YouTube

Guidance from the European Association for Hemophilia and Allied Disorders and the European Hemophilia Federation on managing inhibitorshas been summarised in a video is now available on the EHC YouTube channel. Each of the ten sections of the guidance is summarised in a voiceover with major headings onscreen, over footage of non-specific scenes of young …

Read article
March 4, 2019
New NHS unit to oversee digital transformation

A new organisation is being created to drive forward the adoption of digital technology in the NHS. Christened NHSX, it will provide leadership on national policy “both by working with industry and via its own prototyping and development capability”. Its chief executive will have strategic responsibility for directing technological development and will be accountable to …

Read article
March 3, 2019
UK haemophilia centre staff unclear about dentistry guidance

UK staff involved in the treatment of haemophilia know about guidelines for management during dental procedures but not much about what’s in them or how to apply them to assess risk, say dentists (Spec Care Dentist. 2019 Feb 17. doi: 10.1111/scd.12359). They sent questionnaires to 180 staff working in 60 UK centres, of whom 41 …

Read article
March 2, 2019
Bleeding risk the same for vaginal and Caesarean delivery

The incidence of major bleeds and intracranial haemorrhage associated with vaginal delivery and Caesarean section are similar, a new analysis of the PedNet database has shown (Haematologica 2019 Feb 21. doi: 10.3324/haematol.2018.209619). The study included 926 neonates (786 with severe and 140 with moderate haemophilia) in hospitals in Europe and Israel. About two-thirds were delivered …

Read article
March 1, 2019
New EHL factor VIII approved in US

The US Food and Drug Administration has approved Novo Nordisk’s extended half-life factor VIII for prophylaxis and treatment in children and adults with severe haemophilia A. Turoctocog alfa pegol (Esperoct) is a pegylated version of Novo’s recombinant factor VIII NovoEight. The company says that, compared with standard factor VIII, half-life is increased by a factor …

Read article